Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 13,457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft-Versus-Host Disease (cGVHD) Clear all
Withdrawn Not applicable Interventional

Probiotic Use in Patients With Prior COPD Exacerbation

NCT02185092
View directory record Official record
Conditions
COPD, Obstructive Lung Disease
Interventions
Lactobacillus GG, Sugar pill
Dietary Supplement · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2

NCT01624792
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Muscle Wasting
Interventions
Olive oil, Fish oil, Fish oil and placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 15, 2026, 9:06 AM EDT
Active, not recruiting Phase 1 Interventional

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

NCT05823571
View directory record Official record
Conditions
Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
Interventions
Itacitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 9:06 AM EDT
Recruiting Phase 3 Interventional

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

NCT07020819
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
Tanruprubart
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 15, 2026, 9:06 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

NCT02393807
View directory record Official record
Conditions
Healthy
Interventions
PF 06260414 solid dose formulation, PF-06260414 nanosuspension
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

NCT00777036
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

NCT01185028
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Nitazoxanide With Pegylated Interferon And Ribavirin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

BPD Saturation TARgeting

NCT03385330
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Chronic Lung Disease
Interventions
LOWER oxygen saturation target group, HIGHER oxygen saturation target group
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
34 Weeks to 44 Weeks
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 15, 2026, 9:06 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)

NCT06253507
View directory record Official record
Conditions
p47, Autosomal Recessive, Chronic Granulomatous Disease
Interventions
Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

NCT00800007
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
ANZ-521, Placebo
Drug
Lead sponsor
Anza Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Anaheim, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

NCT01966107
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions
Aclidinium Bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
3,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
433
States / cities
Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

NCT00275509
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Phase 1 Interventional

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

NCT04203875
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
Orencia® (Abatacept)
Drug
Lead sponsor
Stuart Knechtle, M.D.
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

NCT00002779
View directory record Official record
Conditions
Lymphoma
Interventions
fludarabine phosphate, octreotide acetate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2015
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Balloon REmodeling Antrostomy THErapy Study

NCT00645762
View directory record Official record
Conditions
Sinusitis
Interventions
RS-Series Rhinosinusitis Treatment System, FinESS Balloon
Device
Lead sponsor
Entellus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Fresno, California • Evanston, Illinois • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 15, 2026, 9:06 AM EDT
Completed No phase listed Observational

Intrathecal Therapy for Chronic Non-Cancer Pain: An Analysis of Its Efficacy

NCT01564069
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 15, 2026, 9:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Flow Response and Acute INterval Exercise

NCT04673994
View directory record Official record
Conditions
Stroke, High Intensity Interval Exercise
Interventions
Single, acute bout of high intensity interval exercise
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Results available

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

NCT02058251
View directory record Official record
Conditions
Alcohol Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Results available

Hormone Function in Men Treated for Pain With Opioids or Placebo

NCT00737737
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis
Interventions
MS Contin, Placebo
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
30 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Compassion Training and Pain

NCT01776645
View directory record Official record
Conditions
Chronic Pain
Interventions
Compassion Cultivation Training Course
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Telephone Cognitive Behavior Therapy for OEF Veterans With Pain

NCT01236196
View directory record Official record
Conditions
Chronic Pain
Interventions
Telephone cognitive behavior therapy, Telephone pain education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 15, 2026, 9:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Follow-up of AKI in Neonates During Childhood Years

NCT02306642
View directory record Official record
Conditions
Neonatal Acute Kidney Injury, Childhood Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
Matthew Harer, MD
Other
Eligibility
2 Years to 7 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 15, 2026, 9:06 AM EDT
Recruiting Phase 2 Interventional

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT07269470
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Dasatinib, Ropeginterferon alfa-2b (P1101)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 9:06 AM EDT